Secondary analysis of the TREAT EARLIER trial: 44 of 115 (38%) methotrexate-treated patients with clinically suspect arthralgia had an MRI-defined response; ≥2 sites of tenosynovitis, or osteitis plus tenosynovitis, predicted response (PPV 77%, 79%).
Secondary analysisn = 115
Claassen et al. Which arthralgia patients benefit most in reduction of subclinical joint inflammation by methotrexate treatment: results from the TREAT EARLIER trial